Evaxion A (EVAX) Revenue (2024 - 2025)
Evaxion A (EVAX) posted Revenue of $7.5 million for Q3 2025, down 99.98% on a QoQ basis from $37.0 billion in Q2 2025, and up 148.33% year-over-year from $3.0 million in Q3 2024.
Evaxion A (EVAX) Revenue (2024 - 2025) Analysis & Trends
Evaxion A's Revenue history runs 2 years deep, the most recent figure standing at $7.5 million for Q3 2025.
- Quarterly Revenue rose 148.33% year-over-year to $7.5 million in Q3 2025, while the trailing twelve-month figure through Mar 2026 was $37.0 billion (up 1123723.02% YoY) and the FY2025 annual result came in at $7.5 million, up 125.12% from the prior year.
- Revenue was $7.5 million for Q3 2025 at Evaxion A, down from $37.0 billion in the prior quarter.
- Across five years, Revenue topped out at $37.0 billion in Q2 2025 and bottomed at $51000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.51 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 2.99 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 3.61 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 1.30 Bn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Evaxion A | 1.23 Bn | 1.23 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 7.49 Mn |
| Jun 30, 2025 | 37.00 Bn |
| Dec 31, 2024 | 122,000.00 |
| Sep 30, 2024 | 3.02 Mn |
| Jun 30, 2024 | 154,000.00 |
| Mar 31, 2024 | 51,000.00 |